{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:22Z","timestamp":1778754742465,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1 I01 CX000920-01"],"award-info":[{"award-number":["1 I01 CX000920-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["2I01CX000920-04"],"award-info":[{"award-number":["2I01CX000920-04"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.diagmicrobio.2020.115034","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T20:49:34Z","timestamp":1583786974000},"page":"115034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status"],"prefix":"10.1016","volume":"97","author":[{"given":"Brian D.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Thuras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0005","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.01604-13","article-title":"Molecular epidemiology of Escherichia coli sequence type ST131 and its H30 and H30-Rx subclones among extended-spectrum beta-lactamase\u2013positive and \u2013negative E. coli clinical isolates from the Chicago region (2007-2010)","volume":"57","author":"Banerjee","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0010","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1086\/671725","article-title":"Predictors and molecular epidemiology of community-onset extended-spectrum betalactamase-producing Escherichia coli infection in a midwestern community","volume":"34","author":"Banerjee","year":"2013","journal-title":"Infect Control Hosp Epidemiol."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0015","series-title":"Polymorphic and pseudopolymorphic forms of a pharmaceutical compound","author":"Bhattacharya","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0020","doi-asserted-by":"crossref","unstructured":"Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis.16:661-73.","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0025","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1128\/AAC.00160-19","article-title":"Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum \u03b2-lactamases from U.S. hospitals","volume":"63","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb2210","series-title":"M100 29ED: Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0035","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/cid\/cit503","article-title":"Escherichia coli sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans","volume":"57","author":"Colpan","year":"2013","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0040","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.00297-09","article-title":"Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002-2004","volume":"53","author":"Johnson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/653932","article-title":"Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States (2007)","volume":"51","author":"Johnson","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0050","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/AAC.05824-11","article-title":"Molecular epidemiology of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum cephalosporinase-producing E. coli in the United States (2000-2009)","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0055","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/AAC.05824-11","article-title":"Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum cephalosporinase-producing E. coli in the United States (2000-2009)","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0060","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00673-15","article-title":"Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of Escherichia coli sequence type 131 vs. other fluoroquinolone-resistant E. coli","volume":"59","author":"Johnson","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0065","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1128\/AAC.01687-15","article-title":"Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131","volume":"59","author":"Johnson","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0070","doi-asserted-by":"crossref","unstructured":"Johnson JR, Porter S, Thuras P, Castanheira M. The pandemic H30 subclone of sequence type 131 (ST131) is the leading cause of multidrug-resistant Escherichia coli infections in the United States (2011\u20132012). Open Forum Infect Dis. 2017;4:ofx089.","DOI":"10.1093\/ofid\/ofx089"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0075","doi-asserted-by":"crossref","unstructured":"Johnston BD, Thuras P, Johnson JR. Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. PLoS One. 2018;13:e0200442.","DOI":"10.1371\/journal.pone.0200442"},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0085","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1128\/JCM.00346-13","article-title":"Prevalence and characteristics of the epidemic multi-resistant Escherichia coli ST131 clonal group among extended-spectrum \u03b2-lactamase (ESBL)-producing E. coli in Copenhagen","volume":"51","author":"Olesen","year":"2013","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0090","unstructured":"Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of ESBL-producing Escherichia coli ST131 is driven by a single highly virulent subclone, H30-Rx. mBio. 2013;6:e00377-13."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2020.115034_bb0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320301826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320301826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:02:26Z","timestamp":1778752946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320301826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0732889320301826"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115034","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115034"}}